TARO received ANDA Approval for Clobetasol Propionate on July 2nd as can be seen from the FDA's web site. There are only 2 generic suppliers for this product currently in USA. Actavis and TARO. Actavis had 6 month exclusivity which started in January 2012. Investors would recall that Actavis, a comparable peer of TARO, competes in a number of products with TARO. The product listing of TARO and Actavis can be found. Actavis was acquired by Watson in April 2012 at 14.8 TTM EBIDTA.
The Worldwide 2010 sales for Clobetasol Propionate was ~$240m
Combined USA annual brand sales of Clobex® Shampoo and Clobex® Topical Lotion totaled $89.9 million for the 12 months ending September 30, 2011, according to IMS Health.
This is another product that we expect would materially add to the future earnings of TARO.
Disclosure: I am long TARO.